By Sheeba M. | May 20, 2026
MSO Earnings Momentum Signals Shift in Federal Sentiment
The narrative around cannabis MSOs has fundamentally changed in May 2026. After months of regulatory uncertainty and sector pullbacks, top-tier operators are proving the business model works at scale.
Trulieve Cannabis led the charge with Q1 2026 revenues of $582M (+18% YoY) and adjusted EBITDA of $78M. More importantly, the company guided for continued margin expansion through 2026. That’s the kind of predictability institutional LPs have been waiting for.
But it’s not just Trulieve. Curaleaf Holdings reported similar momentum: $635M in Q1 revenue, 20% YoY growth, and management commentary about “normalizing” federal policy creating tailwinds. The tone matters—executives are now comfortable discussing federal legalization timelines publicly.
The Federal Sentiment Shift
Here’s what changed: In the past 60 days, three separate Congressional committees have advanced cannabis banking and rescheduling discussions. This isn’t binding law yet, but it signals the political center has moved. When MSO management teams sense this, they communicate differently to investors.
Green Thumb Industries went one step further, raising their full-year guidance and explicitly citing “improved policy framework assumptions” in their 10-Q. Translation: They’re betting on federal movement and want the Street to know it.
That optimism is trickling down to smaller operators. Jemtrade (Canadian ancillary play) and domestic CBD/hemp players are seeing fresh institutional interest as the sector consolidates around proven MSOs.
For traders, this creates a classic “leadership rotation” setup: Large-cap MSOs are priced in (TRSSF, CURLF, GTBPF already up 12-18% YTD). Money is beginning to hunt for mid-cap upside plays with similar unit economics but lower valuations. Watch for unusual volume on Village Farms and smaller regional chains.
Sources
- SEC EDGAR — MSO quarterly and annual filings (10-Q, 10-K)
- Congress.gov — Bills and committee actions on cannabis policy (HR 3617, S 1689)
- Federal Register — DEA guidance and rescheduling proceedings
Track cannabis stocks with the Weedstock Real-Time Tracker